Clinical trials of neuroprotective therapies.
There have been numerous failures in the field of acute stroke therapy over many years, but the first large clinical trial showing preliminary indications of efficacy and safety of a neuroprotective drug, NXY-059, has now been fully reported. If confirmed, it will mean that a second therapy for acute stroke has been identified and neuroprotective drug development as a class can proceed. Additionally, a new class of drugs, HMG CoA-reductase inhibitors (statins), specifically high-dose atorvastatin, has been shown to be safe and effective for secondary stroke prevention. This drug should now become a regular part of stroke patient care.